(AOF) – Equasens, the specialist in IT solutions for healthcare professionals, has unveiled first-half sales up 9% to 112.62 million euros. The Pharmagest division recorded a turnover of 83.7 million euros, an increase of 9% compared to the same period last year.
In terms of outlook, Equasens is counting on maintaining growth in the second half of 2023 with the release of new products (mobility, security, SaaS offers, etc.) boosting sales, all sectors combined.
The group is also counting on the continued integration of recent acquisitions which should make it possible to enrich the technological offers and accelerate growth.
It “remains attentive to external growth opportunities and has the financial capacity to carry them out”, indicates a press release from the company.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
2023-08-04 04:18:49
#Equasens #halfyear #turnover
